Tarlatamab-Imdelltra is a drug developed by which company?

Tarlatamab (trade name Imdelltra) is a new bispecific T cell-engaging antibody (BiTE), mainly used for the treatment of solid tumors such as small cell lung cancer (SCLC). The drug was developed by Amgen, a world-renowned biopharmaceutical company headquartered in California, USA, and one of the leading companies in the field of immunotherapy and targeted drug research and development.

Talatumumab, as a BiTE antibody, binds to the DLL3 antigen and CD3 receptor on the surface of pan>T cells guides T cells directly to tumor cells to achieve immune killing. This mechanism of action reflects Amgen's advanced technology in the field of bispecific antibodies and tumor immunotherapy.

AmgenDuring the clinical development process, Amgen has conducted multiple phase I/II clinical trials in patients with small cell lung cancer to evaluate the efficacy and safety of talatumumab. Trials have shown that talatumumab can induce tumor remission in some patients with relapsed or refractory SCLC and can be administered via intravenous injection, showing good clinical application prospects.

In general, Tarlatamab (Tarlatamab) is an innovative tumor immunotherapy drug developed by Amgen and represents the cutting-edge achievements of biopharmaceutical companies in the field of bispecific T cell-engaging antibodies. Its research and development background and mechanism provide new hope for the treatment of small cell lung cancer and other tumors with high DLL3 expression, and also reflect the continuous upgrading of current immunotherapy strategies.

Reference materials:https://www.drugs.com/